. IVIg is fractionated from normal plasma and contains over 90% IgG with trace quantities of IgA (depending on the preparation) which is screened for hepatitis B, C, HIV I and II and elevated amidotransferase. Each batch of IVIg is prepared from a pool of 10 000-20 000 healthy blood donors. IVIg thus contains a broad spectrum of the expressed normal human IgG repertoire of antibodies.
No case of documented transmission of HIV or viral hepatitis has been reported with the new formulations which have additional viral inactivation processes like acid treatment and pasteurization.
An early report on the benefit of human placentaeluted gammaglobulin [4] stimulated small clinical studies on the use of IVIg in RA [5] [6] [7] . These studies report initial improvement in clinical and biochemical parameters which do not persist when the treatment is stopped. Tumiati [7] reported that nine out of 10 patients who had failed on at least one DMARD had subjectively and objectively improved within 4 weeks of commencing IVIg and this improvement was maintained by monthly boluses for 6 months. After discontinuation of therapy all patients had a relapse of their disease within 12 weeks, suggesting the effect achieved was not disease remittive.
Emery and colleagues have reported on the first placebo-controlled study of IVIg in 32 patients with early RA who had not received second line agents [8] . The actively treated group had two consecutive days treatment at a dose of 0.5 g/kg/day followed by a single monthly treatment. While there was a significant fall in RF titre and an increase in immune complexes in the actively treated group there was no significant differ-ence in clinical parameters at 1 month. This study casts some doubt on the usefulness of FVIg as a monotherapeutic approach in early RA. However surprisingly the control group also improved after 1 month and the treatment schedule used was not one that has been found useful in any previous study of RA or other conditions. A large early RA treatment study in which the active group received a standard treatment programme (0.4 g/kg/day for 5 days) is clearly needed.
These studies suggest that IVIg may be effective in the short term in many refractory RA patients although its benefit is dependent on continuing treatment. A statistically significant negative correlation between CD8+ cell counts and serum IgG levels was reported in one group of patients unresponsive to IVIg [9] , suggesting that a pronounced reduction in CD8+ cells may be responsible for the lack of benefit in some cases. Tumiati [7] has found that the IVIg-induced reduction in clinical activity paralleled a decrease in the CD4+ CDW29+ : CD4+ CD45RA+ cell ratio in the peripheral blood by increasing the percentage of the CD4+ CD45RA+ 'naive' subset of T lymphocytes. There was no increase in the CD4+ CD W29+ 'memory' T cell subset. After discontinuing IVIg treatment a progressive increase of the ratio to pre-treatment levels was noted. It is not clear whether these lymphocyte phenotypic changes are an epiphenomenon or a direct consequence of IVIg.
Jayne et al. [9] reported the response of seven patients with ANCA-positive vasculitis, four with Wegener's, one with rheumatoid vasculitis, and two with micropolyarteritis. They were treated with IVIg 0.4 g/kg body weight/day for 5 consecutive days. All seven had clinical improvement which was sustained in six and transient in one. A reduction in ANCA titre and acute phase reactants was seen with clinical improvement occurring 2 days to 3 weeks after treatment. None of these seven had severe glomerulonephritis, five had vasculitis unresponsive to conventional immunosuppression whilst two had not received any prior immunomodulatory treatment. During the follow-up of 6-18 months, three patients relapsed. IVIg dramatically improved two ANCA-positive vasculitic patients with aggressive glomerulonephritis unresponsive to cyclophosphamide with associated fall in ANCA titres [11] . A further report noted an improvement in four patients, three with cutaneous vasculitis and one with systemic vasculitis [12] .
Several reports suggest IVIg is useful in treating certain patients with SLE. The first report noted remission of fever, skin vasculitis and buccal ulceration in two paediatric cases [13] . We have successfully treated four severe refractory dermatological lupus patients with IVIg [14] . Other small series report success treating SLE associated thrombocytopenia [15, 16] , pancytopaenia [17] , vasculitic neuropathies [18, 19] and glomerulonephritis with associated nephrotic syndrome [16, [20] [21] [22] . The benefit of treating SLE patients with glomerulonephritis is contentious. Schifferli [23] has reported that patients with the nephrotic syndrome may develop an asymptomatic reversible deterioration in renal function resultant from IVIg treatment while Jordan found that some patients with lupus nephritis deteriorated after IVIg, manifested by an increase in haematuria and proteinuria [24] . It cannot be excluded that the changes in renal function were due to the progression of the disease and other drugs used. A possible explanation for the deterioration observed in some patients may be the variable matching between solubilizing IgG in the FVIg infused and the nephritogenic immune complexes responsible for the disease. Some patients with lupus nephritis have improved clinically and in terms of renal biopsy findings following IVIg therapy [22] and while the numbers of patients treated in these studies have been small the balance of opinion favours a trial of IVIg in lupus patients with active renal disease unresponsive to cyclophosphamide and steroid.
IVIg has been used to treat pregnant women with the lupus anticoagulant and recurrent fetal loss [25, 26] . The authors have treated eight lupus anticoagulantpositive women in nine pregnancies with a total loss prior to treatment of 28 with IVIg [27] . There were six successful outcomes of pregnancy; in one the pregnancy was terminated at 8 weeks because of a blighted ovum giving an overall successful outcome rate of about 70%. Untreated the fetal loss is of the order of 90% [28] .
Patients with poorly controlled polymyositis, despite aggressive immunosuppression, have improved clinically biochemically and in terms of muscle power as assessed by reproducible sphygmometric increases following treatment with IVIg [29, 30] . In JCA patients Silverman et al. [31] reported that IVIg was effective in improving articular and extra-articular features of disease. In addition they were able to reduce the maintenance prednisolone dose and in seven out of eight patients followed for longer than a year steroid was discontinued. However, whether significant improvement is achieved is contentious as the first double blind placebo-controlled study of IVIg demonstrates no greater benefit in the IVIg-treated group [32] . IVIg has been shown to reduce the coronary artery lesions in Kawasaki's disease in a multicentre controlled clinical trial where the dosage used was 400 mg/kg body weight for 4 days [33] . Another trial showed that a single dose of 2 g/kg body weight was equally effective [34] .
How IVIg works is not completely understood. As a result of clinical and experimental studies several mechanisms have been identified and implicated in explaining IVIg's immunomodulatory effects. Interactions between the Fc fragments of infused IgG and Fc receptors on inflammatory cells, lymphocytes and complement components have been described [35] . Fehr has shown that following IVIg treatment of FTP patients there is Fc receptor blockade of splenic macrophages. This may play a critical role in the short-term decrease in platelet clearance, which is one of the mechanisms of action of IVIg in these patients [2] .
Anti-inflammatory effects of Fvlg includes an ability to down-regulate cytokine production and release by activated macTophages resulting from Fc receptor interactions [36] . This effect is considered important in FVIg's effectiveness in Kawasaki's disease [33] . B and T cells functioning may also be modulated in Kawasaki's disease through interactions with Fc receptors on lymphocytes [36] . IVIg by Fc receptor binding may in addition inhibit complement binding and hence complement-mediated damage [37] . The interaction of the Fc component with immune complexes can change the structure and solubility of these complexes as for example in renal lupus patients treated by IVIg [22] . These complexes have been solubilized in vitro by Lin et al. The biopsies studied have heavy IgG deposits along the capillary walls (either Class IV or V lupus nephritis) which were solubilized after incubation with IVIg and human Fc fragments as demonstrated by a dramatic decrease and in some cases disappearance of immunofluorescence. The in vitro findings were mirrored by improvements in serial renal biopsies after treatment.
A number of immunomodulatory effects are thought to result from the vast number of anti-idiotypes contained in IVIg infusions. These include binding of idiotypes of the recipients autoantibodies so neutralizing their effect and facilitating the clearance of the autoantibodies by the reticulo-endothelial system [35] . Idiotypes are antigenic variant binding sites on the variable regions of antibodies and Jerne's postulate that idiotype-anti-idiotype binding plays a pivotal role in the network organization and control mechanism of immunoglobulin synthesis and activity has become increasingly accepted because of the supporting experimental evidence [38] . Anti-idiotypic antibodies may also bind and down regulate the B cell receptor for antigen (an immunoglobulin) thus decreasing autoantibody production [39] . Though less well understood regulatory T cells may recognize anti-idiotypes or a complex of idiotype-anti-idiotype and result in activation or suppression of T cell functions [40] .
IVIg has been shown to contain antibodies reactive with idiotypes of disease-associated autoantibodies including antiplatelet GPIIb/IIIa [41] , and antineutrophil cytoplasm [42] . Anti-idiotype antibody will bind specifically and block disease associated autoantibodies as happens, for example, in FTP [34] . The demonstration of a fall in ANCA titre when ANCAassociated systemic vasculitis has been successfully treated with IVIg may be explained by this effect [10] . Due to the large number of contributing blood donors each IVIg batch has a strong chance of containing cross-reactive idiotypes that will bind disease-associated autoantibodies and pathogenetic T lymphocyte receptors with immunomodulatory consequences.
There is recent evidence that the effects of IVIg are not solely related to the passive transfer of blocking IgG but reflect active and long-lasting immunomodulation. Infusions of IVIg result in increased levels of circulating IgM and total IgG level modifications that cannot reflect simple passive transfer of IgG [43] . There is a measurable difference between pre-and post-FVIg blood samples in terms of antibody activity assessed in vitro [44] . The authors have noted a 5-yr-old child with IgA and IgG subclass immunodeficiency with hypergammaglobulinaemia treated with IVIg replacement therapy in whom following treatment the total IgG and IgM decreased to age-related normal ranges.
An observed immunomodulatory effect of IVIg in RA [7] that is possibly important has been previously discussed. The peripheral blood of RA patients has a relatively low 'naive' CD45RA+ T cell subset compared with their CD4+ CDW29+ 'memory' subset. IVIg has resulted in a peripheral blood increase in the 'naive' subset paralleling a clinical response. A similar increase in 'naive' cells has been found in the synovial cells of a small RA cohort responding to slow-acting antirheumatic drugs [45] . Further studies of the synovial 'naive' cell subset should clarify if IVIg treatment is associated with a similar increase in this T cell subset
IVIg is relatively safe to use. However, side effects of varying severity may occur. Some batches of the earlier IVIg preparations were associated with the transmission of non A non B hepatitis (most probably hepatitis C). Headache is not an uncommon occurrence during or after IVIg infusion. It may occur with chills, myalgia and fever. The vast majority of these reactions can be prevented by a slower rate of infusion, pre-treatment with aspirin or in the case of previous reactions concomitant administration of hydrocortisone. IgA-deficient individuals receiving FVIg may develop anaphylaxis due to the development of antibodies to the administered IgA. IVIg is used in much higher dosage in rheumatological disorders than in IVIg replacement therapy. The passively acquired antibodies may interfere with red cell grouping and antibody testing and cause haemolytic anaemia [46] . Patients receiving high dose IVIg should be cross-matched with the IVIg preparation to be used and a batch with low titre haemagglutinins selected in order to reduce the risk of haemolytic anaemia. Aseptic meningitis has been reported to rarely complicate high dose IVIg [47] .
At present the primary antibody immunodeficiencies, immune thrombocytopaenic purpura and Kawasaki's disease are the conditions for which there is a proven role for IVIg use. IVIg appears to be effective in a number of rheumatological diseases. However, the studies reported to date contain small numbers of patients and most have been uncontrolled. It is clear that there is a need for well-designed controlled trials of IVIg and in systemic vasculitis these are already underway. The novel mechanisms of action of IVIg suggest that further research on IVIg treatment of rheumatological disease will improve our understanding of the immunopathogenesis of these conditions, which may have therapeutic implications.
